相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
2
100.0%
暂无批准数据
- The global oncolytic virus therapy market is projected to grow from USD 21.54 million in 2025 to USD 223.5 million by 2035, at a CAGR of 26.36% during 2026–2035. - Oncolytic viruses selectively infect and destroy cancer cells while stimulating systemic anti-tumor immune responses, transforming "cold" tumors into "hot" ones. - A robust clinical pipeline, including cretostimogene grenadenorepvec, CAN-2409, RP1, and Olvi-Vec, is advancing across melanoma, bladder, lung, and other solid tumors. - Recent regulatory milestones, including FDA accelerated approval of TUDRIQEV (RP1) for advanced melanoma, underscore growing momentum in the field.
- Genelux is actively enrolling patients in a Phase 3 trial for platinum-resistant/refractory ovarian cancer, with topline results expected in the latter half of 2025. - A Phase 2 trial is underway for recurrent non-small cell lung cancer, combining Olvi-Vec with chemotherapy and immune checkpoint inhibitors, with interim data anticipated by mid-2025. - Interim results from a Phase 1b/2 trial in recurrent small cell lung cancer, conducted in collaboration with Newsoara BioPharma, are projected by the end of 2024. - Genelux's cash and investments of $35.1 million are expected to fund operations into the first quarter of 2026, supporting ongoing clinical development programs.
- Genelux has dosed the first patient in a Phase 2 clinical trial (VIRO-25) evaluating Olvi-Vec for recurrent non-small cell lung cancer (NSCLC). - The trial will assess Olvi-Vec's efficacy and safety in combination with platinum-doublet chemotherapy and an immune checkpoint inhibitor (ICI) versus docetaxel. - Olvi-Vec is an oncolytic vaccinia virus being developed as a potential treatment for various cancers, demonstrating a manageable safety profile in prior studies. - Interim data from the Phase 2 trial is expected in mid-2025, potentially offering a new systemic treatment option for NSCLC patients with limited options.
